Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc. (ADIL)
Filing Type: Form 8-K (Current Report)
Date of Report: March 5, 2025
Event: Notice of failure to satisfy Nasdaq continued listing rule regarding minimum bid price.
Key Financial Metrics
This filing is a current report regarding listing status and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Listing Deficiency: The Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days (January 17, 2025, through March 4, 2025).
- Regulatory Status: Received written notice from Nasdaq Listing Qualifications Department on March 5, 2025.
- Trading Status: The notice has no immediate effect; the stock continues to trade on The Nasdaq Capital Market under the symbol "ADIL."
Guidance, Outlook, and Management Commentary
- Compliance Period: The Company has 180 calendar days (until September 1, 2025) to regain compliance.
- Compliance Criteria: Compliance is achieved if the closing bid price is at or above $1.00 for a minimum of ten consecutive business days during the compliance period.
- Secondary Compliance Option: If the bid price requirement is not met by September 1, 2025, the Company may be eligible for an additional compliance period if it meets the market value of publicly held shares requirement and all other initial listing standards.
- Management Action: The Company intends to monitor the bid price and considers available options, including effecting a reverse stock split, to maintain its listing.
Investor Verification Checklist
- Verify the current closing bid price of ADIL stock relative to the $1.00 threshold.
- Monitor the Company's announcement regarding the implementation of a reverse stock split, if deemed necessary.
- Track the stock price performance over the next 10 consecutive business days to assess immediate compliance potential.
- Review the Company's market value of publicly held shares to determine eligibility for a second compliance period if the initial deadline is missed.